ID   P388 Pr8/22
AC   CVCL_4276
SY   Pr8/22; PR8/22; P388R
DR   CLO; CLO_0008482
DR   CancerTools; 153248
DR   ECACC; 93112518
DR   Wikidata; Q54937249
DR   Ximbio; 153248
RX   PubMed=6627597;
RX   PubMed=7917900;
CC   Doubling time: 28.5 hours (PubMed=6627597).
CC   Selected for resistance to: ChEBI; CHEBI_41977; Daunorubicin (Daunomycin).
CC   Transformant: ChEBI; CHEBI_34342; 3-methylcholanthrene (3-MC; 20-methylcholanthrene; 20-MC; MCA).
CC   Discontinued: ECACC; 93112518; true.
CC   Breed/subspecies: DBA/2.
DI   NCIt; C21602; Mouse lymphoma
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_D640 ! P388/S
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 14-08-25; Version: 15
//
RX   PubMed=6627597; DOI=10.1007/BF00254258;
RA   McGown, Alan Thomson
RA   Ward, Timothy H.
RA   Fox, Brian William
RT   "Comparative studies of the uptake of daunorubicin in sensitive and
RT   resistant P388 cell lines by flow cytometry and biochemical extraction
RT   procedures.";
RL   Cancer Chemother. Pharmacol. 11:113-116(1983).
//
RX   PubMed=7917900; DOI=10.1038/bjc.1994.353; PMCID=PMC2033429;
RA   Prendiville, Joseph Aloysius
RA   McGown, Alan Thomson
RA   Gescher, Andreas Johannes
RA   Dickson, Alan J.
RA   Courage, Carol
RA   Pettit, George Robert
RA   Crowther, Derek G.
RA   Fox, Brian William
RT   "Establishment of a murine leukaemia cell line resistant to the
RT   growth-inhibitory effect of bryostatin 1.";
RL   Br. J. Cancer 70:573-578(1994).
//